To better your understanding of non-clinical career options and/or facilitate your physician career change, today we introduce you to Martin Tolar, M.D., Ph.D. Dr. Tolar is Chief Scientific Officer at CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.
Dr. Tolar joined CoMentis in April 2007 as Vice President of Strategic and Corporate Development. In his current position, Dr. Tolar is responsible for R&D strategy, research projects and business development activities.
Dr. Tolar has over 10 years of experience working in the biopharmaceutical industry. He joined CoMentis from Pfizer, where he spent six years in a variety of leadership positions in Neuroscience Clinical Development, Alliance Management, as well as Business Development. As Director of Neuroscience Worldwide Business Development at Pfizer Global Pharmaceuticals, Dr. Tolar chaired the Neuroscience Licensing Team at Pfizer. He was responsible for licensing and outreach activities in Neurology and Psychiatry, including the 2006 acquisition of Rinat Neurosciences and the license of the RAGE platform from TransTech Pharma. Prior to his work in Neuroscience Licensing, Dr. Tolar served as the U.S. Clinical Leader for indiplon, an insomnia treatment developed with Neurocrine Biosciences, where he was responsible for the conduct of clinical trials and the New Drug Application (NDA) filings for immediate and modified release formulations.
Dr. Tolar holds an M.D. degree and trained in Neurology at the Boston Medical Center. In Boston, he also served as Teaching Fellow in Neurology at Boston University School of Medicine and Research Fellow at Massachusetts General Hospital. Dr. Tolar received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease. From 2002 to 2007, Dr. Tolar held an appointment at Yale University School of Medicine, most recently as Assistant Professor in the Department of Neurology. He has published more than 20 scientific publications in the area of Neurosciences and serves on the Scientific Program Committee of the American Society for Experimental NeuroTherapeutics (ASENT).
For more info9rmation about Dr. Tolar or CoMentis, please visit the company website.
